MorphoSys announced that Lucinda Crabtree, Ph.D., will join MorphoSys as Chief Financial Officer and member of the Management Board, succeeding Sung Lee. She will start in the third quarter 2023 at the latest. Lucinda Crabtree joins MorphoSys from Autolus Therapeutics, a clinical-stage biopharmaceutical company developing T cell therapies, where she most recently served as Chief Financial Officer.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MOR:
